Target
Integrin Alpha IIb Beta 3
Description
Anti-Integrin Alpha IIb Beta 3 Antibody, Non-Fucosylated (BioBet-1120ZP) is a human monoclonal IgG antibody against Integrin Alpha IIb Beta 3. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Thrombosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Integrin Alpha IIb Beta 3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Integrin αIIbβ3
Full Name
Integrin Alpha IIb Beta 3
Background
In medicine, glycoprotein IIb/IIIa (GPIIb/IIIa, also known as integrin αIIbβ3) is an integrin complex found on platelets. It is a receptor for fibrinogen and von Willebrand factor and aids in platelet activation. The complex is formed via calcium-dependent association of gpIIb and gpIIIa, a required step in normal platelet aggregation and endothelial adherence. Platelet activation by ADP (blocked by clopidogrel) leads to the aforementioned conformational change in platelet gpIIb/IIIa receptors that induces binding to fibrinogen. The gpIIb/IIIa receptor is a target of several drugs including abciximab, eptifibatide, tirofiban.
Alternative Names
Integrin αIIbβ3; Integrin Alpha IIb Beta 3; GPIIb/IIIa; glycoprotein IIb/IIIa; ITGA2B; ITGB3
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with ITGA2B include Glanzmann Thrombasthenia and Bleeding Disorder, Platelet-Type, 16.
Related Pathways
Its related pathways are RET signaling and Integrin Pathway.
Function
Integrin alpha-IIb/ -3 is the receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It can recognize R-G-D sequences in a variety of ligands. It recognizes the H-H-L-G-G-G-A-K-Q-A-G-D-V sequence in the fibrinogen gamma chain. After activation, integrin alpha-IIb/ -3 causes platelet/platelet interaction by binding to soluble fibrinogen. This step leads to rapid platelet aggregation, physically blocking the surface of ruptured endothelial cells.
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Immune System antibody; Signaling Transduction antibody
Post-translational modifications
1.Glycosylation at Asn46, Asn280, Asn601, Asn711, Ile874, Ser878, and Asn962 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
The integrin αIIbβ3 specific antibody are used for treatment to prevent thrombosis in conditions selected from the group consisting of pulmonary embolism, transient ischemic attacks (TIAs), deep vein thrombosis, coronary bypass surgery, and surgery to insert a prosthetic valve or vessel in autologous, non-autologous, or synthetic vessel graft. A further embodiment contemplates using the antibody that specifically immunoreacts with integrin αIIBβ3 as a medicament for treatment to prevent thrombosis.
Antibody Indication
Thrombosis
